As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Analysts suggested that the tariffs will have little effect on reshoring manufacturing and will likely decrease patient drug ...

The National Security Commission on Emerging Biotechnology recommends at least a $15 billion investment into biotech over the ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...